TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6135433

Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: minaxolone
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: di-isopropyl phenol
Number of subjects: 4

Group type: COMPARATOR
Intervention: halothane
Number of subjects: 4
Study: 30882162

Group type: COMPARATOR
Intervention: Cleansing of the perianal skin using povidone‐iodine cotton balls (Group I, n=165)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Injection of povidone‐iodine solution (0.1 g/mL) into the anal and lower rectal canals (Group II, n=116)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Direct manual cleansing of the mucosal surface of the anus and lower rectum using povidone‐iodine cotton balls (Group III, n=170)
Number of subjects: 451
Study: 30739745

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target systolic blood pressure 130-140 mm Hg within 1 h)
Number of subjects: 2196

Group type: COMPARATOR
Intervention: Guideline blood pressure lowering (target systolic blood pressure <180 mm Hg)
Number of subjects: 2196

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 2196

Group type: COMPARATOR
Intervention: Guideline blood pressure lowering
Number of subjects: 2196
Study: 29266839

Group type: EXPERIMENTAL
Intervention: Same-day 1-L polyethylene glycol (1-L PEG)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Split-dose 4-L polyethylene glycol (4-L PEG)
Number of subjects: 44
Study: 26465792

Group type: EXPERIMENTAL
Intervention: LYM-X-SORB™ (LXS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 25004921

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 µg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.9% normal saline (control group)
Number of subjects: 120
Study: 22339553

Group type: EXPERIMENTAL
Intervention: Topical product for night-time application aimed at adipolysis and microcirculation stimulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20596066

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment based on traditional Chinese medicine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study: 18265875

Group type: EXPERIMENTAL
Intervention: Gastrointestinal helminth infection
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Mild eosinophilia
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Marked eosinophilia
Number of subjects: 387
Study: 16111418

Group type: EXPERIMENTAL
Intervention: Mobile phone digital images
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional X‐ray box
Number of subjects: 14
Study: 12368570

Group type: EXPERIMENTAL
Intervention: 5 mg olmesartan medoxomil q.d.
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: 20 mg olmesartan medoxomil q.d.
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: 80 mg olmesartan medoxomil q.d.
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: 2.5 mg olmesartan medoxomil b.i.d.
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: 10 mg olmesartan medoxomil b.i.d.
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: 40 mg olmesartan medoxomil b.i.d.
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study: 10202830

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate 65 mg weekly
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate 195 mg weekly
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate 200 mg fortnightly (open-label)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DEXA, BIS, D2O methods
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BIS method
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7851572

Group type: EXPERIMENTAL
Intervention: Initial hCG titer < 1,000 mIU/mL
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Trend in hCG titers between first and second sample
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ultrasonographic visualization of absence of an ectopic gestational sac
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Initial hCG titer and trend in hCG titers
Number of subjects: 67
Study: 1967338

Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emergency hepatic transplantation
Number of subjects: 0
Study: 335419

Group type: EXPERIMENTAL
Intervention: Piracetam (3 tablets or 1.2 g for second and third graders; 5 tablets or 2.0 g for fourth graders)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 30535534

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, Lactobacillus fermentum, 2 × 10^9 CFU/g each) for 6 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 48
Study: 27511906

Group type: EXPERIMENTAL
Intervention: Active acupuncture (AA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 42
Study: 24447266

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (6 ml.h(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% ropivacaine (6 ml.h(‐1))
Number of subjects: 60
Study: 23739196

Group type: EXPERIMENTAL
Intervention: Ulimorelin 160 µg/kg
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Ulimorelin 480 µg/kg
Number of subjects: 662

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 662
Study: 20545209

Group type: EXPERIMENTAL
Intervention: Fupiyiwei decoction (FPYWD) combined with chemotherapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (chemotherapy only)
Number of subjects: 58
Study: 17368874

Group type: EXPERIMENTAL
Intervention: Structured medium and long chain triglycerides (StO)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Extra virgin olive oil (OO)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both diets (StO and OO)
Number of subjects: 23
Study: 15935270

Group type: EXPERIMENTAL
Intervention: Direct restorations
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Semi-direct restorations
Number of subjects: 11
Study: 12841885

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/day) continuously
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (0.625 mg/day) and medroxyprogesterone acetate (5 mg/day) continuously
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg/day) continuously (hysterectomized women)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (50 microg/day) and medroxyprogesterone acetate (5 mg/day) continuously
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (50 microg/day) continuously (hysterectomized women)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 212
Study: 11299497

Group type: EXPERIMENTAL
Intervention: 1.2 g i.v. amoxicillin/clavulanic acid (Group 1)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Other antibiotics commonly used for prophylaxis (Group 2)
Number of subjects: 435

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (Group 3)
Number of subjects: 435
Study: 1996000

Group type: EXPERIMENTAL
Intervention: Standard dose of epinephrine (1 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High dose of epinephrine (0.2 mg/kg)
Number of subjects: 32
Study: 6350014

Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte alpha 2 interferon (rIFN) at various dosages (0.3 X 10(6) IU, 1 X 10(6) IU, 3 X 10(6) IU, 10 X 10(6) IU, 30 X 10(6) IU, 100 X 10(6) IU)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low dose (0.01 X 10(6) IU)
Number of subjects: 27
Study: 30690609

Group type: EXPERIMENTAL
Intervention: TheraBracelet stimulation during task-practice therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 12
Study: 30429694

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 26735516

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Long-pulsed Nd:YAG laser
Number of subjects: 20
Study: 24499959

Group type: EXPERIMENTAL
Intervention: Group T1 (T1/Tc ratio of 50%)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Group TOF (maintenance of two train‐of‐four counts)
Number of subjects: 61
Study: 22311445

Group type: EXPERIMENTAL
Intervention: Omeprazole + Amoxicillin + Clarithromycin (OAC group)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Metronidazole (OAM group)
Number of subjects: 85
Study: 20023578

Group type: EXPERIMENTAL
Intervention: Intellectual disability group (ID)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Syndromic etiology among individuals with ID
Number of subjects: 77
Study: 17947836

Group type: EXPERIMENTAL
Intervention: Telecare (glucometer transmission with feedback, group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (standard communication by phone and face-to-face visits, group B)
Number of subjects: 28
Study: 16290959

Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Estrogen plus medroxyprogesterone acetate
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Estrogen and estrogen plus medroxyprogesterone
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Estrogen (active treatment arm)
Number of subjects: 232
Study: 11981142

Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lorazepam (active placebo)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (dose-response)
Number of subjects: 44
Study: 10772554

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg (two doses)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control (uninfected children at baseline)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Decrease in Trichuris intensity
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Decrease in Ascaris intensity
Number of subjects: 103
Study: 7554327

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 11
Study: 1766725

Group type: EXPERIMENTAL
Intervention: OPV‐OPV‐OPV (Group A)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: IPV‐IPV‐IPV (Group B)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: IPV‐OPV‐OPV (Group C)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: IPV‐IPV‐OPV (Group D)
Number of subjects: 123
Study: 7250471

Group type: EXPERIMENTAL
Intervention: Salicylic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water/oil emulsion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urea
Number of subjects: 0
Study: 31794624

Group type: EXPERIMENTAL
Intervention: Traditional Section 8 voucher
Number of subjects: 4604

Group type: EXPERIMENTAL
Intervention: Low-poverty voucher
Number of subjects: 4604

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4604
Study: 28810024

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (n=64) including 5 to 6 weekly aerobic training sessions (30-60 minutes) and dietary plans aiming for a BMI of 25 or less.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard care (n=34) with individual counseling and standardized medical therapy.
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (n=64)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard care (n=34)
Number of subjects: 98
Study: 26905272

Group type: EXPERIMENTAL
Intervention: Real rTMS + CIMT
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham rTMS + CIMT
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Real rTMS + CIMT and Sham rTMS + CIMT
Number of subjects: 14
Study: 25090043

Group type: EXPERIMENTAL
Intervention: Internet-based community reinforcement approach intervention plus contingency management (CRA+) and buprenorphine
Number of subjects: 170

Group type: COMPARATOR
Intervention: Contingency management alone (CM-alone) plus buprenorphine
Number of subjects: 170
Study: 22292521

Group type: EXPERIMENTAL
Intervention: Individualized treatment based on early treatment response
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard treatment based on early treatment response
Number of subjects: 192
Study: 19053020

Group type: EXPERIMENTAL
Intervention: Mild increased physical activity (walking about 800 meters/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Habitual activity
Number of subjects: 8
Study: 17805102

Group type: EXPERIMENTAL
Intervention: Prednisolone (60 mg.d(‐1) for 1 wk)
Number of subjects: 10
Study: 15196525

Group type: EXPERIMENTAL
Intervention: Ankle arthrodesis fused in a neutral position
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (walking barefoot)
Number of subjects: 19
Study: 12380850

Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 324

Group type: COMPARATOR
Intervention: Nonrandomized trials
Number of subjects: 324
Study: 9810581

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No patellar resurfacing (Group B)
Number of subjects: 40
Study: 8129501

Group type: EXPERIMENTAL
Intervention: CME (Continuing Medical Education)
Number of subjects: 3158

Group type: EXPERIMENTAL
Intervention: CME+QA (Continuing Medical Education with Quality Assurance)
Number of subjects: 3158

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3158

Group type: EXPERIMENTAL
Intervention: CME vs Control
Number of subjects: 3158

Group type: EXPERIMENTAL
Intervention: CME+QA vs CME
Number of subjects: 3158
Study: 2187928

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Netilmicin and azlocillin
Number of subjects: 34
Study: 6107725

Group type: EXPERIMENTAL
Intervention: 1 mg DAMME (FK33-824, Sandoz) infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water-deprived volunteers (after DAMME administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrated subjects
Number of subjects: 0
Study: 31006694

Group type: EXPERIMENTAL
Intervention: Dual-task training using various cognitive tasks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional occupational therapy
Number of subjects: 30
Study: 27714763

Group type: EXPERIMENTAL
Intervention: Amiselimod (1 mg·kg‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiselimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fingolimod (1 mg·kg‐1)
Number of subjects: 0
Study: 25881262

Group type: EXPERIMENTAL
Intervention: Daily provision of free fruit and vegetables (FV)
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Promotion of a pleasant eating environment
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Daily offering of FV by teachers
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Cutting up FV by teachers
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: High implementation of educational components
Number of subjects: 1121
Study: 23666608

Group type: EXPERIMENTAL
Intervention: Golimumab 50 or 100 mg every 4 weeks
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 405
Study: 22072405

Group type: EXPERIMENTAL
Intervention: Telemedicine Cognitive Behavioral Therapy (TV‐CBT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Face-to-Face Cognitive Behavioral Therapy (FTF‐CBT)
Number of subjects: 116
Study: 19131420

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Insertion of tympanostomy tubes with adenoidectomy
Number of subjects: 166

Group type: COMPARATOR
Intervention: Insertion of tympanostomy tubes without adenoidectomy
Number of subjects: 166
Study: 17471295

Group type: EXPERIMENTAL
Intervention: Behavioral and pharmacological treatment
Number of subjects: 180
Study: 15071400

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 10
Study: 11333047

Group type: EXPERIMENTAL
Intervention: Overdrive pacing at 60 bpm
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overdrive pacing at 75 bpm
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overdrive pacing at 90 bpm
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard lower rate limit of 60 bpm
Number of subjects: 18
Study: 9725752

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0
Study: 8039612

Group type: EXPERIMENTAL
Intervention: Lymphapheresis (9 procedures within 4-5 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lymphapheresis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 2568520

Group type: EXPERIMENTAL
Intervention: Calcium-heparin, 12,500 U, subcutaneously
Number of subjects: 711
Study: 5342

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30995905

Group type: EXPERIMENTAL
Intervention: Intervention (INT)
Number of subjects: 1550
Study: 28556806

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle (PFM) exercises with simultaneous tension of the transverse abdominal muscle (TrA) for 3 months, 4 weekly sessions
Number of subjects: 140

Group type: COMPARATOR
Intervention: Pelvic floor muscle (PFM) exercises without TrA tension for 3 months, 4 weekly sessions
Number of subjects: 140
Study: 24977700

Group type: EXPERIMENTAL
Intervention: Caffeine (6.04 +/- 0.16 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23597658

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention emphasizing 'Stand Up, Sit Less, Move More'
Number of subjects: 43
Study: 21240873

Group type: EXPERIMENTAL
Intervention: Everolimus + CsA + steroids
Number of subjects: 106

Group type: COMPARATOR
Intervention: EC‐MPS + CsA + steroids
Number of subjects: 106
Study: 19295192

Group type: EXPERIMENTAL
Intervention: Supplementation with n‐3 long‐chain polyunsaturated fatty acids (FAs)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Isocaloric control diet
Number of subjects: 204
Study: 16597671

Group type: EXPERIMENTAL
Intervention: Logistic transformation applied to bounded outcome scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic transformation with equal variances
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ignoring inequality of variances
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation study comparing performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Application of methods on two data sets
Number of subjects: 0
Study: 15217964

Group type: EXPERIMENTAL
Intervention: Gefitinib (Iressa) as second-line therapy
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Gefitinib in combination with chemotherapy (first-line therapy)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Gefitinib (not specified)
Number of subjects: 1000
Study: 11704778

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: Ranitidine 25 mg
Number of subjects: 1620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg and 25 mg
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 1620
Study: 9152715

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7535550

Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 32
Study: 3321153

Group type: EXPERIMENTAL
Intervention: Dextro-propranolol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31584721

Group type: EXPERIMENTAL
Intervention: Marriage Checkup (two‐session Assessment and Feedback relationship intervention)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Waitlist-Control Condition
Number of subjects: 209
Study: 27900849

Group type: EXPERIMENTAL
Intervention: Wristband (WB) and smartphone application (APP) with personalized feedback every 7 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard approach (low-energy diet and physical activity prescription)
Number of subjects: 36
Study: 27270279

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodiafiltration (CVVHDF)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High dosing regimens (≥25 mg/kg) and extended intervals (36 to 48 h)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Extended-interval high loading dose of amikacin (25 mg/kg every 48 h) with therapeutic drug monitoring (TDM)
Number of subjects: 16
Study: 25705964

Group type: EXPERIMENTAL
Intervention: Preoperative cognitive-behavioral intervention (CBT) and usual care
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 90
Study: 24349782

Group type: EXPERIMENTAL
Intervention: Folic acid 4.0 mg supplementation throughout pregnancy
Number of subjects: 3656

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3656
Study: 20634744

Group type: EXPERIMENTAL
Intervention: Sagittal Plane (SP) Plyometrics
Number of subjects: 32

Group type: COMPARATOR
Intervention: Frontal Plane (FP) Plyometrics
Number of subjects: 32
Study: 17765233

Group type: EXPERIMENTAL
Intervention: EmbryoGlue as the embryo transfer medium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard culture media
Number of subjects: 0
Study: 16914390

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Diet and exercise + niacin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Diet and exercise + fenofibrate
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Diet and exercise + niacin and fenofibrate
Number of subjects: 200